CHANGE IN RATINGS
downgraded at Friedman, Billings: AMH was downgraded from Outperform to Market Perform, Friedman, Billings Ramsey said. Stock is now trading within 2% of Aviva's $69 takeover offer.
upgraded at JP Morgan: CKH was upgraded from Neutral to Overweight, JP Morgan said. Core businesses should continue to perform well, because of strong demand and tight capacity. Estimates also increased.
rated new Outperform at Credit Suisse: Credit Suisse said it is initiating coverage on CTSH with an Outperform rating. Believes environment for offshore remains strong and company's strong brand name and its investments in sales should lead to strong revenue. Sets $80 target price.
rated new Outperform at Credit Suisse: Credit Suisse said it is initiating coverage on GLW with an Outperform rating. Believes LCD TV cycle is only in second inning. Sets $24 target price.
downgraded at UBS: UBS downgraded KFT to Reduce from Neutral and lowered its price target to $32 from $35. 2006 estimates were lowered two cents to $1.95 and 2007 estimates were reduced to $2.01 from $2.10. The company could see increasing input cost inflation which may not be offset by pricing.
downgraded at Friedman, Billings: Rating on N was lowered to Market Perform, Friedman, Billings Ramsey said. Upside limited, following the $77 a share cash bid from CVRD. PD offers better value, at current levels.
STOCK COMMENTS / EPS CHANGES
estimates raised at Goldman: Goldman said it is raising its 2006 EPS estimates on A to $1.51 from $1.43 after solid F3Q results. Maintained Neutral rating and $33 target price.
estimates reduced at Jefferies: Jefferies said it is cutting its 2006 estimates on ADCT to $0.60 from $0.82 based on lowered outlook and company guidance. Maintained Equal-weight rating. No price target.
outlook cut at Morgan Stanley: Morgan Stanley said it is lowering its estimates on ADCT for the full year to 60 cents a share from 82 cents a share. Maintained Equalweight rating.
price target raised at Piper: Piper raised its price target on BOBJ to $32 from $25 since shares now trade at an attractive valuation and that greater M&A activity could provide a bottom. Maintains Outperform rating.
estimates lowered at Goldman: Goldman said it is lowering its 2006 EPS estimates on CA to 82 cents from 87 cents following F1Q results. Believes restructuring plan will be slow and expensive. Maintained Sell rating.
price target decreased at Jefferies: Jefferies said it is reducing its target on CRM to $28 from $31 due to a lack of near-term proof of operating leverage improvements. Reiterated Hold rating.
estimates increased at Jefferies: Jefferies said it is increasing its 2006 estimates on EQIX by 5 cents to $(0.54) after company beat Q2 expectations and reaffirmed full year guidance. Reiterated Buy rating.
target cut at Morgan Stanley: Morgan Stanley said it is reducing its price target on HEW to $25 from $27 due to slowing economy and rising compensation costs. Maintained Equal-weight rating.
target price lowered at Goldman: Goldman said it is lowering its target price on HEW to $21 from $23 following 3Q results. Believes it will take a few quarters for confidence in company's execution to build. Maintained Sell rating.
estimates cut at Morgan Stanley: Morgan Stanley said it is lowering its estimates on HEW for the full year to a loss of 98 cents a share from $1.25 a share. Maintained Equalweight rating.
estimates raised at Jefferies: 2007 estimates on HLSH raised 4 cents to $0.03, Jefferies said. Company plans to reposition itself as a pure-play inpatient rehab provider. Results appear to be stabilizing in light of operational challenges. Reiterated Hold rating.
estimates raised at UBS: UBS raised its 2006 estimates on MHS to $2.63 from $2.60 and 2007 estimates to $3.17 from $3.11. Maintained Buy rating and $74 price target.
outlook raised at Morgan Stanley: Morgan Stanley said it is raising its estimates on PPP for the full year to $4.44 a share from $4.39 a share. Maintained Underweight rating.
target price cut at Credit Suisse: Credit Suisse said it is cutting its target price on PSUN to $15 from $19. Expects continued weakness in sales going forward. Maintained Underperform rating.
outlook cut at Goldman: Goldman said it is lowering its 2006 EPS estimates on STI by 8 cents to $5.92 to account for slower net interest income growth than previously estimated. Lowered target price to $89 from $90.
price target reduced at UBS: UBS reduced its price target on STI a dollar to $90, 2006 estimates to $6 from $6.05 and 2007 estimates to $6.55 from $6.60 after its disappointing credit announcement. Maintains Buy rating due to a strong credit environment and the company's conservative track record.
estimates raised at UBS: UBS raised its 2007 estimates on SYY a penny to $1.61 based on an improved earnings outlook. Maintained Buy rating and $39 price target.
price target upped at Morgan Stanley: Morgan Stanley said it is increasing its price target on USB by a dollar to $33 based on higher credit quality and increased share buybacks. Maintain Equal-weight rating.
outlook raised at Morgan Stanley: Morgan Stanley said it is increasing its estimates on XTO for the full year to $4 a share from $3.87 a share. Maintained Overweight rating and $54 a share.